Bibliographic Details
| Title: |
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. |
| Authors: |
Lord, Simon R.1,2,3 (AUTHOR) simon.lord@oncology.ox.ac.uk, Collins, Jennifer M.4 (AUTHOR), Cheng, Wei-Chen1 (AUTHOR), Haider, Syed5 (AUTHOR), Wigfield, Simon2 (AUTHOR), Gaude, Edoardo6 (AUTHOR), Fielding, Barbara A.4,7 (AUTHOR), Pinnick, Katherine E.4 (AUTHOR), Harjes, Ulrike2 (AUTHOR), Segaran, Ashvina1 (AUTHOR), Jha, Pooja8 (AUTHOR), Hoefler, Gerald8 (AUTHOR), Pollak, Michael N.9 (AUTHOR), Thompson, Alastair M.10 (AUTHOR), Roy, Pankaj G.11 (AUTHOR), English, Ruth.12 (AUTHOR), Adams, Rosie F.12 (AUTHOR), Frezza, Christian6 (AUTHOR), Buffa, Francesca M.1 (AUTHOR), Karpe, Fredrik3,4 (AUTHOR) |
| Source: |
British Journal of Cancer. Jan2020, Vol. 122 Issue 2, p258-265. 8p. 1 Diagram, 4 Graphs. |
| Subject Terms: |
*PROTEIN kinases, *RESEARCH, *XENOGRAFTS, *ANIMAL experimentation, *RESEARCH methodology, *DIABETES, *CELL physiology, *GENETIC disorders, *EVALUATION research, *MEDICAL cooperation, *MITOCHONDRIA, *COMPARATIVE studies, *GENE expression profiling, *GENES, *RESEARCH funding, *METFORMIN, *LIPID metabolism disorders, *FATTY acids, *BREAST tumors, *OXIDATION-reduction reaction, *LIPID peroxidation (Biology), *MICE, *PHARMACODYNAMICS |
| Abstract: |
Background: Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing the potential of repurposing this drug are underway. Transcriptomic profiling of tumour samples is an excellent tool to understand drug bioactivity, identify candidate biomarkers and assess for mechanisms of resistance to therapy.Methods: Thirty-six patients with untreated primary breast cancer were recruited to a window study and transcriptomic profiling of tumour samples carried out before and after metformin treatment.Results: Multiple genes that regulate fatty acid oxidation were upregulated at the transcriptomic level and there was a differential change in expression between two previously identified cohorts of patients with distinct metabolic responses. Increase in expression of a mitochondrial fatty oxidation gene composite signature correlated with change in a proliferation gene signature. In vitro assays showed that, in contrast to previous studies in models of normal cells, metformin reduces fatty acid oxidation with a subsequent accumulation of intracellular triglyceride, independent of AMPK activation.Conclusions: We propose that metformin at clinical doses targets fatty acid oxidation in cancer cells with implications for patient selection and drug combinations.Clinical Trial Registration: NCT01266486. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
